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Rationale: Aspergillus fumigatus (A. fumigatus) in cystic fibrosis (CF) is
increasingly recognized. Although allergic bronchopulmonary as-
pergillosis (ABPA) leads to deterioration of pulmonary function,
the effect of A. fumigatus colonization in the absence of ABPA
remains unclear.
Objectives: To address this, we examined individuals with CF with
A. fumigatus who were ABPA negative to identify the effects of itra-
conazole therapy on Aspergillus-induced lung inflammation.
Methods: The effect of A. fumigatus on nuclear vitamin D receptor
(VDR)expressionwas investigatedusingqRT-PCRandWesternblot-
ting. IL-5 and IL-13 levels were quantified by ELISA. The effect of
itraconazole was assessed by a combination of high-resolution com-
puted tomography, lung function test, andmicrobiological analysis.
Measurements and Main Results: We demonstrate that A. fumigatus
down-regulates VDR in macrophages and airway epithelial cells
and that the fungal metabolite gliotoxin (Gt) is the main causative
agent. Gt overcame the positive effect of 1,25-OH vitamin D3 on
VDR expression in vitro, resulting in increased IL-5 and IL-13
production. In vivo, A. fumigatus positivity was associated with
increased Gt in CF bronchoalveolar lavage fluid and increased
bronchoalveolar lavage fluid levels of IL-5 and IL-13. After airway
eradication of A. fumigatus with itraconazole, we observed de-
creased Gt, IL-5 and IL-13, improved respiratory symptoms, and
diminishedhigh-resolution computed tomographymosaic pattern
consistent with sustained pulmonary function.
Conclusions: This study provides a rationale for the therapeutic ef-
fect of itraconazole and implied that the therapeutic potential of
vitamin D supplementation in preventing ABPA is only feasible
with concurrent elimination of A. fumigatus to permit VDR expres-
sion and its positive functional consequences.
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itraconazole; inflammation
Cystic fibrosis (CF) is a systemic heritable disorder. Pathogenesis
of lung disease induced by CF is a direct result of decreased chlo-
ride secretion and hyperabsorption of sodium, resulting in the
retention of dehydrated mucus within the airways. Pathogenic
colonization and chronic infection occurs, giving rise to recurrent
exacerbations, respiratory failure, and death.
Our understanding of the airway microbiome within the CF
milieu has evolved with fungi emerging as recognized colonizers
and potential pathogens (1–4). Although yeasts and filamentous
fungi are identified in CF, the most commonly isolated member
of the latter group is Aspergillus fumigatus. In the immune-
competent host, exposure to A. fumigatus spores leads to an
immune response stimulating prompt fungal clearance. Occasion-
ally, however, in immunocompromised individuals, this ubiqui-
tous fungus can cause life-threatening invasive disease. In most
cases, although it is acknowledged as a potential problem, the
impact of A. fumigatus on airway disease and inflammation in
CF remains unclear (4).
Colonization rates vary between centers. In one decade-long
study, A. fumigatus was isolated in over one third of lung cultures
from people with CF (5), a proportion similar to that detected by
our group (6). Additionally, we and others have demonstrated
that the frequency of A. fumigatus isolation from CF sputum does
not correlate with rates of allergic bronchopulmonary aspergillosis
(ABPA), gender, pancreatic status, or cirrhosis but is associated
with higher recovery rates of Pseudomonas aeruginosa infection
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AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
In individuals with cystic fibrosis, the effect of azole treat-
ment on patients with Aspergillus fumigatus colonization in
the absence of allergic bronchopulmonary aspergillosis is
unknown.
What This Study Adds to the Field
Aspergillus colonization increases T-helper 2 cytokine pro-
duction by structural and innate immune cells of the airways.
The mechanism of action involves down-regulation of vita-
min D receptor expression. The overall effect of itracona-
zole treatment was elimination of A. fumigatus bioburden,
thereby permitting vitamin D receptor expression, resulting
in decreased T-helper 2 cytokine production and significant
clinical improvement.
(6, 7). Moreover, exposure of cystic fibrosis transmembrane con-
ductance regulator (CFTR)-deficient mice to A. fumigatus anti-
gens leads to a severe pulmonary Th2-biased inflammatory
phenotype, suggesting that in CF, even in the absence of ABPA,
A. fumigatus acts unfavorably (8). In addition, vitamin D defi-
ciency has been proposed as a risk factor for CF-ABPA as
reduced levels of IL-5 and IL-13 expression were recorded
after in vitro treatment with vitamin D (9). Further support
for this theory is provided by research illustrating that deletion
of vitamin D receptor (VDR) results in elevated IL-5 and IL-13
production (10) and pulmonary inflammation (11).
The role of A. fumigatus colonization in the absence of
ABPA remains a subject of uncertainty. It has been shown that
pulmonary radiological abnormalities on high-resolution com-
puted tomography (HRCT) are more pronounced in an
A. fumigatus–colonized cohort compared with a matched non–
Aspergillus-colonized CF group, a finding not reflected by pul-
monary function testing alone (12). A. fumigatus colonization
has additionally been shown to be an independent risk factor for
hospital admission in CF (1, 13), yet studies assessing the effect
of eradication of A. fumigatus from the CF airway unaffected by
ABPA are limited. Although work on azole-based agents (e.g.,
itraconazole or voriconazole) in CF-ABPA is ongoing, the anti-
inflammatory effects of vitamin D and other VDR agonists in
the setting of A. fumigatus colonization without ABPA remain
unaddressed. This study clarifies the effect of A. fumigatus on
VDR expression in the CF airway and for the first time eval-
uates treatment effectiveness of itraconazole in A. fumigatus
colonization without ABPA. Some of the results of these stud-
ies have been previously reported in the form of an abstract
(14–16).
METHODS
Patient Selection and Recruitment
All patients with CF attending Beaumont Hospital, Dublin, Ireland, be-
tween July 2008 and June 2010 (2-yr period) were screened for study
eligibility (n ¼ 117) (see Figure E1 in the online supplement). Inclusion
criteria required a confirmed diagnosis of CF by sweat chloride con-
centrations greater than 60 mmol/l on at least two separate occasions
and subsequent confirmatory genotyping. Patients included had to be
colonized with A. fumigatus. Colonization was defined as detection of
the fungus in sputum and/or bronchoalveolar lavage fluid (BALF) on
at least two separate and consecutive occasions at least 12 weeks apart
in the year before study commencement. Before recruitment, patients
had to be exacerbation free over the preceding 6-week period with no
prior diagnosis of ABPA (as per classical consensus conference crite-
ria) (17). Exclusion criteria included allergies to any azole related sub-
stances, prior lung transplantation, and either a confirmed or suspected
diagnosis of ABPA or prior administration of systemic corticosteroid
therapy in any form. All participants had serum IgE levels less than 450
ng/ml and negative cutaneous reactivity to Aspergillus antigens before
the start of the study. Ethical approval from Beaumont Hospital Insti-
tutional Review Board was acquired, and written informed consent was
obtained from all study participants during the screening/baseline (pre-
treatment) visit (Figure E1). Demographics of recruited patients (n ¼
13) are outlined in Table E1 in the online supplement. CT imaging,
pulmonary function testing, Cystic Fibrosis Questionnaire Revised
(CFQ-R) respiratory scoring, and observational study protocols are
outlined in the online supplement.
Sputum, Bronchoalveolar Lavage, and Bronchial
Brushing Samples
Spontaneously expectorated sputum from a deep cough was collected at
each study visit. Sputum was divided into two sterile containers and
transported immediately for evaluation. Suitability of sputum samples
for study inclusion was confirmed by the criteria used to determine rep-
resentative sputum samples (3). A single patient was a nonproducer;
hence, BALF was used instead and obtained by standard methods (18).
A total of four samples per patient were obtained and processed over
the 1-year study course (52 samples). Bronchial brushings were also
obtained before and after itraconazole treatment (n ¼ 3) from
A. fumigatus–positive or A. fumigatus –negative patients (n ¼ 3) not on
treatment (age in years 6 SD, 24.33 6 4.45; gender [% male/female],
50:50; FEV1% predicted 6 SD, 38.83 6 13.37; BMI 6 SD, 20.95 6 1.84;
plasma vitamin D levels 6 SD, 47.66 6 26.31 ng/ml) and processed as
previously described (19). A full description of the procedures pertaining
to the bronchial brushings can be found in the online supplement.
For processing of CF sputum or BALF for A. fumigatus coloniza-
tion, an equal volume of Sputasol (Oxoid Ltd, Basingstoke, UK) was
added to each sputum sample (no Sputasol was added to BALF), which
was then shaken for 15 minutes at 378C. The A. fumigatus status of
homogenized sputum or BALF from each patient sample was deter-
mined in triplicate as colony forming units (CFU), and the concurrent
equivalent number of conidia per gram of sputum as evaluated (a full
protocol can be found in the online supplement). The occurrence of
airway colonizers (e.g., P. aeruginosa and Staphylococcus aureus) were
identified by standard microbiological methods as outlined by the Cys-
tic Fibrosis Trust (20). In vitro cell culture, preparation of Aspergillus
culture supernatants, and treatment of human bronchial epithelial cells
or macrophages is described in the online supplement.
Statistical Analysis
Descriptive analyses are presented as means (6 SD or SE), medians,
or proportions depending on whether the data were normal, non-
normal, or categorical. Continuous data were tested for normality
(Kolmogorov-Smirnoff or Shapiro Wilk tests as appropriate) and
where normal were compared using a Student t test (paired or unpaired
where appropriate). For nonnormal data, the Mann-Whitney U test
was performed for comparisons. Tests for trends over time were con-
ducted using repeated measures ANOVA for normally distributed
data, and post hoc multiple comparison tests (Tukey’s test) were ap-
plied. Friedmans chi-square test was used to compare trends over time
for nonnormal (nonparametric) data. For count data (e.g., number of
infective exacerbations), log-linear (poisson) regression analysis was
performed using Generalized Estimating Equations for repeated mea-
sures within each patient. All statistical analyses were performed using
the PRISM 4.0 software package (GraphPad, San Diego, CA) and SAS
(v9.1; SAS Institute Inc., Cary, NC). Differences were considered sig-
nificant at P < 0.05.
RESULTS
The Effect of A. fumigatus Culture Filtrates on VDR Gene
and Protein Expression in CF Tracheal Epithelial and CF
Bronchial Epithelial Cells
We and others have previously shown that A. fumigatus colo-
nization affects approximately one third of people with CF (5,
6), an observation further confirmed in this study (Figure E1).
The percentages of dominant immune cells in A. fumigatus–
colonized CF BALF has been previously reported to include
neutrophils (61%) and macrophages (31%) and, to a much
lower extent, lymphocytes (4%) (21). By Western blotting, how-
ever, VDR protein expression was found abundant in macro-
phages but not in neutrophils and at a very low level in T cells
(Figure E2). CF airway epithelial cells were also found to ex-
press VDR protein, and consequently this study examined the
effect of A. fumigatus on VDR expression by structural (bron-
chial and tracheal epithelial cells) and immune cells (macro-
phages) of the airways.
VDR gene expression was significantly down-regulated by
approximately 80% in CF tracheal epithelial (CFTE) cells
(P ¼ 0.001) (Figure 1A) and was completely inhibited in CF
bronchial epithelial (CFBE) cells (P ¼ 0.04) (Figure 1B) in
response to treatment with 3-day culture filtrates for 16 hours.
VDR gene expression was decreased by approximately 33%
2 hours after addition of Aspergillus culture filtrate in CFTE
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cells (Figure 1C) and was significantly down-regulated in CFTE
and CFBE cells by approximately 50% after 5 hours of expo-
sure to 3-day cultures (P ¼ 0.04) (Figures 1C and 1D, respec-
tively). Maximal effect was observed by treating CFBE cells
with 4-day fungal culture filtrates for 5 hours, with total elimi-
nation of VDR gene expression observed (P ¼ 0.04) (Figure
1E).
The effect of A. fumigatus culture filtrates (1–4 d) on VDR
protein expression was evaluated by Western blotting. Signifi-
cant down-regulation of VDR protein expression was observed
in CFTE and CFBE cells after treatment with 4-day culture
filtrates for 5 hours (P ¼ 0.01 and P ¼ 0.009, respectively)
(Figures 1F and 1G). To confirm the effect of Aspergillus colo-
nization on VDR gene expression in vivo, bronchial brushings
were performed on Aspergillus-positive (Asp1; n ¼ 3) and
Aspergillus-negative (Asp2; n ¼ 3) patients. qRT-PCR con-
firmed significant down-regulation of VDR gene expression
in vivo in Aspergillus-colonized patients, in line with in vitro
results (P ¼ 0.02) (Figure 1H). Collectively these results indi-
cate in vitro and in vivo down-regulation of VDR gene and
protein expression by A. fumigatus.
Down-regulation of VDR Expression by Gliotoxin, an
Immunomodulatory Mycotoxin from A. fumigatus
The VDR modulator present within culture filtrates of A. fumi-
gatus (ATCC 26933) was characterized. The inhibitory activity
was stable within culture filtrates stored at 2708C and subse-
quently used against CFBE cells at 378C but was significantly
abolished by heat inactivation (998C) for 20 minutes (P ¼ 0.003)
(Figure 2A). Passage of culture filtrates through a 3 kD
exclusion filter removed approximately 65% of the VDR
inhibitory activity (P ¼ 0.007), which suggested the presence
of predominantly low-molecular-weight (, 3 kD) VDR inhib-
itory factors.
Secreted by the hyphal form of A. fumigatus, gliotoxin (Gt)
has previously been characterized as a small, heat-inactivated
toxin of 326.4 daltons (22). Gt has been shown to provoke air-
way inflammation and tissue damage with consequential long-
term airway remodeling (23). To confirm Gt as a fungal agent
capable of VDR down-regulation, the effect of a low–Gt-
producing A. fumigatus strain (CaF1) on VDR expression was
explored. Strain CaF1 produced minimal levels of Gt compared
with the high–Gt-producing strain ATCC-26933 after 96 hours
of fungal growth (2 6 0.05 and 252 6 2.5 ng/mg hyphae, respec-
tively) (Figure E3). Moreover, VDR expression in CFTE and
CFBE cells remained relatively unchanged when treated with 1-
to 4-day culture filtrates of CaF1, in comparison to the ATCC-
26933 strain, which resulted in significant down-regulation of
VDR (P ¼ 0.01 and P ¼ 0.009 for CFTE and CFBE cells com-
pared with untreated cells, respectively) (Figures 2C and 2D).
The clinical relevance of these findings was confirmed when
BALF obtained from Aspergillus-positive patients illustrated
high levels of Gt, as quantified by HPLC analysis of chloroform
extracts (Figure 2E).
The effect of purified Gt on VDR expression by CF and non-
CF cells was next explored. By HPLC analysis of cultures of
A. fumigatus strain ATCC-26933, no significant difference was
detected in Gt levels produced on Day 3 (280 6 29 ng/mg
hyphae) compared with Day 4 (252 6 2.5 ng/mg hyphae)
(P . 0.05) (Figure E3A). This concentration produced by the
fungus equates to approximately 0.8 mM commercial Gt, which
was therefore used in this study. Gt used at this concentration
significantly down-regulated VDR protein expression in CFBE
Figure 1. Culture filtrates of As-
pergillus fumigatus down-regulate
vitamin D receptor (VDR) gene
and protein expression. Cystic
fibrosis tracheal epithelial (CFTE)
(A and C) and cystic fibrosis
bronchial epithelial (CFBE) (B
and D) cells (1 3 105) were
untreated (Con) or treated with
3 days of A. fumigatus (ATCC-
26933) culture filtrates (AFCF)
for 16 hours (A and B) or 0 to
5 hours (C and D). RNA was iso-
lated and analyzed for VDR
gene expression by qRT-PCR
and standardized to glyceral-
dehyde 3-phosphate dehydro-
genase (GAPDH). VDR gene
expression was significantly
down-regulated at 16 hours
and at the earlier time point of
5 hours after treatment (C and
D). CFBE cells were treated for 5
hours with 4-day fungal culture
filtrates, with total down-
regulation of VDR gene ex-
pression observed (E). (F and
G) Western blot analysis of VDR protein expression of CFTE (F) and CFBE (G) cells (1 3 106) treated with AFCF (0- to 4-d cultures). Western blots were
probed with mouse monoclonal VDR or rabbit polyclonal GAPDH (loading control) antibodies. The Western blot illustrated is a representative result of one
out of three separate experiments and converted to densitometry units in respective graphs. VDR protein expression was significantly down-regulated by 4-
day cultures. (H) Bronchial brushings were obtained from subjects with CF who were positive (Asp1) (n ¼ 3) and negative (Asp2) (n ¼ 3) for Aspergillus
colonization and analyzed for VDR gene expression by qRT-PCR. VDR gene expression was significantly down-regulated in subjects with CF colonized with
Aspergillus compared with those noncolonized by Aspergillus. All experiments were performed in triplicate on three consecutive days. Data shown are
mean 6 SE.
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cells (P ¼ 0.03) to a similar level obtained after exposure to
4-day culture filtrates of A. fumigatus (ATCC-26933), indicating
that Gt is most likely the main VDR inhibitory factor secreted
by the fungus (Figure E3B).
In vitro studies further revealed that 0.8 mM Gt significantly
down-regulated VDR gene expression in CFTE (P ¼ 0.001),
CFBE (P ¼ 0.02), and human bronchial epithelial (HBE)
(P ¼ 0.003) cell lines (Figures 3A–3C, respectively). HBE cells
were used in this latter experiment to provide evidence that
down-regulation of VDR by Gt was independent of dysfunc-
tional CFTR. In addition, CFBE cells cultured under sub-
merged monolayer (Figure 3D) or air–liquid interface (Figure
Figure 2. Characterization of
the Aspergillus virulence factor
responsible for vitamin D re-
ceptor (VDR) down-regulation.
(A) Down-regulation of VDR
protein expression was re-
versed by heat inactivation
(HI) of A. fumigatus (ATCC-
26933) culture filtrates (AFCF).
Cystic fibrosis bronchial epi-
thelial (CFBE) cells (1 3 106)
were untreated (Con) or ex-
posed to 4 days of AFCF or
HI-AFCF for 5 hours. The West-
ern blots illustrated are from
one representative experiment
out of three and converted to
densitometry units in respec-
tive graphs. (B) VDR is down-
regulated by a small (, 3 kD)
secreted molecule. AFCF (4 d)
was passed through a 3 kDmem-
brane, and the resulting flow
through (FT , 3 kD) or top su-
pernatant (AFCF SUPn .3 kD)
was added to CFBE cells (1 3
106) for 5 hours. (C and D) The
effect of CaF1 (white bars) and
ATCC-26933 (black bars) AFCF
grown for 1 to 4 days on
VDR protein expression in cystic
fibrosis tracheal epithelial (CFTE)
(C) and CFBE cells (D). (E) Levels
of Gt in A. fumigatus colonized cystic fibrosis BALF (n ¼ 3, Asp1) compared with noncolonized samples (n ¼ 3; Asp2). Gt was quantified by HPLC and
standardized to total BALF protein (mg). All assays were performed in triplicate on three consecutive days. Data shown are mean 6 SE.
Figure 3. Effect of purified gliotoxin on vitamin D receptor
(VDR) expression. (A–C) Purified gliotoxin (Gt) down-
regulates VDR in a dose-dependent manner. VDR gene
expression of cystic fibrosis tracheal epithelial (CFTE) (A),
cystic fibrosis tracheal bronchial (CFBE) (B), and human
bronchial epithelial (HBE) (C) cells (1 3 105) treated for
5 hours with 0.16 or 0.8 mM Gt. RNA was analyzed by
qRT-PCR, normalized to glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH), and compared with untreated
cells (Con). (D–F) Gt down-regulates vitamin D–induced
VDR protein expression in vitro. CFBE cells cultured under
submerged monolayer (1 3 106) (D) or air–liquid interface
(5 3 105) (E) or U937 differentiated macrophages (1 3
106) (F) were untreated (Con) or exposed to 1,25D3
(1029 M) in the presence or absence of Gt (0.8 mM) for
24 hours, and VDR protein expression was analyzed by
Western blotting using mouse monoclonal VDR and rabbit
polyclonal GAPDH antibodies. All assays were standardized
to GAPDH and were performed in triplicate on three sep-
arate days. Data shown are mean 6 SE.
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3E) treated with 1,25D3 in the presence of 0.8 mM Gt exhibited
significant down-regulation of VDR protein expression com-
pared with cells treated with 1,25D3 only (P ¼ 0.04 and P ¼
0.005, respectively). This effect was also observed by treating
macrophages with Gt (P ¼ 0.03) (Figure 3F). Control experi-
ments indicated that Gt did not affect cell viability or induce
cell apoptosis as determined by trypan blue exclusion assays or
a lack of cleaved (17/19 kD) caspase-3, respectively (result not
shown). Collectively these experiments suggest an overwhelm-
ing inhibitory effect of Gt on VDR expression.
Gliotoxin Enhances the Production of Th2 Cytokines, Which
Are Reduced after Itraconazole Treatment
It has been shown that VDRknockoutmice have elevated levels of
IL-5 and IL-13 production (10), and vitamin D has also been
observed to modulate Aspergillus-induced Th2 cytokines IL-5
and IL-13 expression in CD41 T cells (9). In line with this, we
investigated the effect of Gt on IL-5 and IL-13 expression in vitro.
CFBE cells or macrophages were treated with 1,25D3 (10
29 M) in
the presence or absence of 0.8 mM Gt. Gt significantly increased
IL-5 and IL-13 gene (Figures 4A and 4B) and protein (Figures
4C–4F) expression in CFBE submerged monolayers (P ¼ 0.05
and P ¼ 0.05, respectively) (Figures 4A and 4B), air–liquid inter-
face CFBE cultures (P ¼ 0.05 and P ¼ 0.01, respectively) (Figures
4C and 4D), and macrophages (P ¼ 0.05 and P ¼ 0.05, respec-
tively) (Figures 4E and 4F). In support of this result, high levels of
IL-5 and IL-13 were observed in CF BALF samples before itra-
conazole treatment (Figures 4G and 4H). After itraconazole treat-
ment, a significant decrease in IL-5 (P ¼ 0.01) and IL-13 (P ¼
0.002) protein expression was detected in vivo, suggesting a role
for itraconazole in reducing the Th2 inflammatory response in
these patients.
Itraconazole Treatment Effectively Reduces A. fumigatus
Bioburden in CF Airways
Itaconazole therapy administered orally at 400 mg once daily for
a 6-week period significantly reduced A. fumigatus bioburden
within the CF airway over time as determined by CFU and co-
nidia counts per gram of sputum and/or BALF (Figures 5A and
5B). Itraconazole therapy was well tolerated in the study cohort,
with no reports of adverse effects or liver dysfunction during
treatment and follow-up. Although CFU counts remained low
at the 12-month follow-up (Figure 5A), A. fumigatus conidia
burden was increased when compared with the 6-month follow-
up sample (Figure 5B), suggesting that qPCR is a more reliable
method of Aspergillus detection in CF sputum. In addition, cor-
responding to a reduction in Aspergillus bioburden at the 12-
month follow-up, levels of Gt were significantly reduced in vivo
from approximately 250 6 80 to 75 6 50 ng/mg BALF protein
(P ¼ 0.04) (Figure 5C). Moreover, after 6 weeks of itraconazole
(400 mg daily) treatment for Aspergillus infection, VDR gene
expression was significantly increased by greater than 2-fold
(P ¼ 0.04) (Figure 5D). This set of experiments demonstrates
that itraconazole therapy significantly reduced A. fumigatus col-
onization within the CF airways and by corollary diminished
Gt levels initiating up-regulation of VDR expression.
A. fumigatus Is Associated with a Mosaic Pattern on HRCT That
Significantly Attenuates after Itraconazole Therapy
It has been shown that A. fumigatus colonization in CF has
adverse effects upon the lung parenchyma (on HRCT) that
do not correlate with pulmonary function testing (12). To es-
tablish the presence of radiological changes after eradication of
A. fumigatus from the CF airway, HRCT scans were performed
Figure 4. Gliotoxin (Gt)-enhanced production of Th2 cytokines is
reduced after itraconazole treatment. (A–D) Gt exposure results in
increased production of Th2 cytokines IL-5 and IL-13 in vitro.
Cystic fibrosis bronchial epithelial (CFBE) monolayer cells (1 3 105)
(A and B), CFBE cells grown under air liquid conditions (5 3 105)
(C and D), and U937 differentiated macrophages (1 3 106) (E and F)
were untreated (Con) or exposed to Gt (0.8 mM) alone or to 1,25D3
(1029 M) in the presence or absence of Gt for 24 hours. IL-5 (A) or IL-
13 (B) gene expression was analyzed by qRT-PCR and standardized
to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). IL-5
(C and E) or IL-13 (D and F) protein expression was quantified by
ELISA. Assays were performed in triplicate on three separate days. (G
and H) IL-5 and IL-13 in vivo cytokine expression is reduced after
itraconazole treatment. IL-5 (G) and IL-13 (H) levels in healthy
control subjects (n ¼ 3, Con) and in Aspergillus-positive cystic
fibrosis bronchoalveolar lavage (BALF) before (n ¼ 3) or after
itraconazole treatment (n ¼ 3) were quantified by ELISA. Assays
illustrated in C and D were performed a minimum of three times in
duplicate and normalized to total BALF protein. Data shown are
mean 6 SE.
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in people with CF colonized byA. fumigatus with no prior history
of ABPA or corticosteroid treatment for suspected ABPA (n ¼
13). Three HRCT scans were performed at baseline (pretreat-
ment), at 10 weeks after completion of itraconazole (posttreat-
ment), and at 12-month follow-up.
No significant differences in the overall or component parts of
the modified Bhalla score was identified after treatment or during
follow-up. However, 92.3% (n ¼ 12) of baseline (pretreatment)
scans illustrated a mosaic pattern, which was significantly less
evident after itraconazole eradication of A. fumigatus. Fewer
scans after treatment (76.9%; n ¼ 10) or during follow-up
(53.8%; n ¼ 7) illustrated evidence of the mosaic pattern ob-
served at baseline (Figures 6A and 6B). In patients in whom
attenuation rather than elimination of the pattern occurred
after itraconazole treatment, we further quantified the mosaic
pattern by its conspicuity (obvious, subtle, or present on expi-
ratory images only) and by percentage of lung parenchyma
involved. A significantly diminished conspicuity and a lower
percentage of lower lobe lung parenchymal involvement after
treatment and during follow-up was observed (Figure 6C).
Pulmonary function (FEV1 and forced expiratory flow, mid-
expiratory phase [FEF25–75]) remained stable without significant
deterioration over the study course (Figure 6D). However,
eradication of A. fumigatus from the CF airway resulted in
a significant reduction in the number of infective exacerbations
(Figure 6E) and requirement for intravenous antibiotic therapy
(Figure E4), findings that were sustained over the study follow-up
period. Respiratory symptoms (assessed by CFQ-R) illustrated
significant improvement during follow-up that was maintained
to study conclusion (Figure 6F). Additionally, mean serum lev-
els of IgE decreased after treatment (178.2 6 88.4 to 136.9 6
60.7 IU/ml) and during follow-up (90.56 32.0 IU/ml), albeit not
significantly (P . 0.05). No patient developed ABPA over the
course of the study. Radioallergosorbent test Aspergillus sam-
pling validated this. In summary, these results indicate that
eradication of A. fumigatus from the CF airway resulted
in improved HRCT appearances, less infective exacerbations,
fewer requirements for intravenous antibiotics, and improved
CFQ-R respiratory symptom scores.
DISCUSSION
In the current study, we illustrate that A. fumigatus colonization
down-regulates VDR and identify Gt as one fungal agent re-
sponsible for mediating this effect. We also found that in vivo
A. fumigatus colonization is associated with increased Gt in CF
BALF, mosaic pattern on HRCT, and an enhanced production
of the Th2 cytokines IL-5 and IL-13. Treatment with the anti-
fungal agent itraconazole in vivo rescued VDR expression, sig-
nificantly attenuated Gt levels, and decreased the production of
the Th2 cytokines IL-5 and IL-13, which drive the allergic pro-
cess leading to ABPA (24, 25). Such eradication of A. fumigatus
from the CF airway resulted in improved respiratory symptoms
and diminished HRCT mosaic pattern, consistent with sustained
pulmonary function.
Vitamin D influences the inflammatory and immune state in
CF and acts via cognate nuclear VDR (26, 27). Although insuf-
ficient vitamin D (, 30 ng/ml) is problematic for bone health in
CF, it is also acknowledged as a risk factor for ABPA in those
colonized with A. fumigatus (9, 28). Consequently, supplemental
administration of vitamin D is advocated for its potential to pre-
vent ABPA (9). As a result, the protein level of VDR through
which vitamin D functions is clinically relevant but has not been
investigated thoroughly in the context of CF complicated by
A. fumigatus. In this study, we illustrate that A. fumigatus colo-
nization in the absence of ABPA down-regulates VDR and en-
hances Th2 cytokine production through Gt, a toxin released by
the hyphal form of the fungi. Compromised VDR in the face of
A. fumigatus disrupts the inflammatory state in CF, with vitamin
D unable to exert its positive impact. One method by which
Figure 5. Aspergillus bioburden is significantly reduced in
the cystic fibrosis (CF) lung after itraconazole therapy,
resulting in increased vitamin D receptor (VDR) expres-
sion. (A) Colony-forming units (CFU) of A. fumigatus per
gram of spontaneously expectorated sputum were deter-
mined in subjects with CF (n ¼ 13) before (Pre) and after
(Post) treatment with itraconazole (400 mg orally once
daily for 6 wk) and at 6 and 12 months. All CFU counts
were performed in triplicate for each patient sample. **P,
0.001 (Friedman’s test; Q ¼ 20.59). (B) The equivalent A.
fumigatus conidia number was determined in the same
patient group (n ¼ 13) using qPCR and A. fumigatus
primer probe sets targeting the 28S rRNA region. DNA
extraction for each patient sample was performed in du-
plicate, and qPCR was performed at least in triplicate.
**P , 0.01 (Friedman’s test; Q ¼ 15.12). (C) Gliotoxin
(Gt) levels in vivo are reduced as a consequence of itracon-
azole treatment. Gt levels were quantified in cystic fibrosis
bronchoalveolar lavage (BALF) before (n ¼ 3) or after itra-
conazole treatment (n ¼ 3) by HPLC and normalized to
total BALF protein (mg) and analyzed by paired t test. (D)
After itraconazole treatment, VDR gene expression is up-
regulated in Aspergillus-colonized patients in vivo. Bronchial
brushings were obtained from people with cystic fibrosis
before (n ¼ 3) or after itraconazole treatment (n ¼ 3), and
VDR gene expression was analyzed by qRT-PCR standard-
ized to glyceraldehyde 3-phosphate dehydrogenase
(GAPDH). The assay was performed in triplicate. Data
shown are the mean 6 SD (A and B) or 6 SE (C and D).
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vitamin D confers benefit is by attenuating Th2 responses to
A. fumigatus by CD41 T cells in CF-ABPA (9). Th2 cytokines
IL-5 and IL-13 are not restricted to CD41 cells alone, and, al-
though this source remains of primary concern in the ABPA
context, release of these cytokines by eosinophil and mast cells
(29, 30), and by airway epithelial cells and macrophages as shown
in the present study, is of importance in people with CF colonized
by A. fumigatus but unaffected by ABPA.
The unique structural motif of Gt is essential for its damaging
effects, including the inhibition of immune cell activation, phago-
cytosis, and ciliary beat frequency, together preventing fungal
clearance (22, 31, 32). Gt concentrations have been reported
in the setting of a murine model of invasive aspergillosis (33);
however, to our knowledge this is the first study to report Gt
levels in vivo in the context of CF and its relationship to VDR
expression. However, Gt-mediated VDR down-regulation is in-
dependent of CFTR dysfunction; this phenomenon was ob-
served during in vitro experiments using non-CF HBE cells.
Gt is also able to overcome the positive effects conferred by
vitamin D on VDR expression, a novel mode of action within
the pulmonary milieu. Placing our findings in the context of
those reported by Kriendler and colleagues (9), vitamin D
may attenuate Th2 cytokines and potentially reduce or prevent
CF-ABPA, although it requires the presence of VDR to carry
out such functions. Hence, the elimination of Gt remains as
crucial as the administration of vitamin D.
This observational study provided unique insights into the
treatment effectiveness of itraconazole on microbiological, ra-
diological, and clinical outcomes, the former two not addressed
by prior work (34). Sputum culture alone has been previously
reported as insufficient at detecting the presence of A. fumiga-
tus in CF (6, 35). Despite this, CFU counts for A. fumigatus
remain the most accessible and affordable method of assess-
ment and therefore remain in routine clinical practice. Failure
to detect A. fumigatus because of a negative sputum culture can
have deleterious clinical consequences. In view of this, we chose
Figure 6. Itraconazole therapy
in Aspergillus fumigatus–
colonized patients demon-
strates radiological and clinical
improvement. Sixty-four–slice
high-resolution computed to-
mography (HRCT) imaging of
the thorax was performed in
13 subjects with cystic fibrosis
before treatment, 10 weeks af-
ter treatment, and at 12-month
follow-up. (A) A representative
pretreatment HRCT image
through the lower lobes ob-
tained at end expiration. There
is an obvious and conspicuous
mosaic pattern involving 80%
of the lung parenchyma. (B)
Follow-up HRCT image at the
same level in the same patient
at 12 months obtained at end-
expiration. There is a dramatic
reduction in the degree of mo-
saic pattern in conspicuousness
and extent. (C) The percentage
of lung parenchyma (within the
lower lobes) illustrating amosaic
pattern was determined. A sig-
nificant attenuation of mosaic
pattern was detected over time,
greatest at late follow-up. ***P¼
0.0019 (Friedman’s test; Q ¼
12.56). (D) Pulmonary func-
tion as percent predicted FEV1
and forced expiratory flow,
midexpiratory phase (FEF25–75)
was evaluated before and after
treatment and during follow-
up at 6 and 12 months. No
significant deterioration of
FEV1 or FEF25–75 occurred over
the course of the study. (E)
Mean number of infective exacerbations defined by the criteria outlined by Fuchs and colleagues (38) was recorded for the 3-month period before-
and after treatment and reassessed at 6 and 12 months. Infective exacerbations significantly decreased after treatment and during follow-up, *P ,
0.001 (log-linear Poisson regression analysis). (F) Changes in respiratory symptoms determined by the cystic fibrosis questionnaire-revised (CFQ-R)
respiratory symptom scale. Respiratory symptoms significantly improved at 6- and 12-month follow-up after treatment. **P ¼ 0.015 (repeat
measures ANOVA; F ¼ 3.99); *P , 0.05 between pretreatment and 6- or 12-month follow-up. Data shown are the mean scaled score for the
respiratory domain of the CFQ-R (out of maximum 100) 6 SD.
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to assess for the presence of A. fumigatus from sputum using
two separate approaches, CFU counts and qPCR for A. fumi-
gatus conidia burden. Although itraconazole was effective at
eliminating A. fumigatus after treatment, these effects were
sustained over the 1-year follow-up by both methodologies.
However, despite the reassuring CFU counts obtained at the
1-year time point, escalations of A. fumigatus conidia burden
were detectable by qPCR at this time as compared with earlier
time points, suggesting a slow return of A. fumigatus coloniza-
tion and the potential need for retreatment. These data provide
evidence to support use of qPCR as the optimal detection
method for A. fumigatus from respiratory CF samples. How-
ever, the clinical parameters assessed in this study continue to
show positive effects at 12 months after treatment, a time when
qPCR counts for A. fumigatus conidia begin to slowly rise (35).
Consequently, cost and clinical importance of such methods for
A. fumigatus detection must be considered before recommend-
ing their routine use. Most benefit from such methodology is
probably gained from its use in clinical scenarios of strongly
suspected A. fumigatus–associated disease in the presence of
negative sputum culture where a treatment decision is necessary
and further microbiological evidence for such treatment is
sought. This may be applicable to A. fumigatus beyond CF.
Further work performed by our group described the radiolog-
ical evaluation of A. fumigatus colonization in CF (12) and
reported a novel mosaic pattern associated with such coloniza-
tion in the CF setting unrelated to ABPA. Quantification of this
mosaic pattern over the study course and after itraconazole
treatment illustrated elimination or significant attenuation, sug-
gestive of an inflammatory benefit in the individuals with CF
recruited to this study. Significant time-dependent effects, great-
est at 12-month follow–up, were observed. Whether such find-
ings confer prolonged benefit or represent a radiological lag in
appearance compared with clinical benefit remains to be eluci-
dated. Although images from an untreated placebo controlled
group of A. fumigatus colonized patients with CF without
ABPA would have provided stronger evidence for this radio-
logical relationship, we feel it would have been unethical to
recruit an untreated group in view of our previously published
work illustrating worse radiological appearances in patients who
areA. fumigatus colonized (12). Although our study findings are
of interest, the small study population and the uncontrolled and
open-label nature of the trial are notable weaknesses. However,
itraconazole treatment produced positive outcomes across all
the clinical parameters assessed, including decreasing exacerba-
tions and stabilizing pulmonary function while improving CFQ-R
respiratory scores, findings contrasting prior work (34). Moreover,
itraconazole is a potent inhibitor of CYP3A4 activity, and cor-
ticosteroids are partly metabolized through such enzymes;
hence, it should be noted that a proportion of our patient cohort
received inhaled corticosteroids at a low dose during the course
of the study (Table E1). Systemic absorption of such steroid use
is accepted to be diminutive; hence, the effects on the CYP3A4
system conferred by itraconazole treatment during the study are
probably minimal. However, this is a potential confounding
factor to be considered when interpreting our results. No pa-
tient during the study developed ABPA by consensus criteria
(17), and a reduced likelihood of ABPA occurring was demon-
strated by decreasing levels of IgE, radioallergosorbent test to
Aspergillus, and an attenuated Th2 cytokine response after
treatment.
Despite the fact that IL-5 and IL-13 are linked to ABPA, none
of the patients recruited to this study had ever hadABPA, although
high levels of these cytokines were present in their lungs. These Th2
cytokines were significantly reduced after itraconazole therapy,
which is suggestive of an important antiinflammatory role for the
drug in addition to its antifungal properties. Minimal clinical data
exist within the CF literature to assist the clinician in identifying
individuals at risk of ABPA or those that can be predicted to de-
velop ABPA in the setting of A. fumigatus colonization alone.
Although our group has previously shown that sputum isolation
of A. fumigatus does not correlate with occurrence of ABPA (6),
the current study has uncovered high levels of Th2 cytokines IL-5
and IL-13 existing in vivo in the setting of A. fumigatus coloniza-
tion without ABPA that may be attenuated by empirical itraco-
nazole treatment. Whether such therapy can prevent ABPA in the
long term in those asymptomatically colonized by A. fumigatus
remains to be determined.
In summary, although published work has suggested the
therapeutic potential of vitamin D in preventing ABPA (9),
our data imply that this approach is only feasible with concur-
rent elimination of A. fumigatus with itraconazole to permit
VDR expression. This study raises awareness of the clinical
importance of antifungal resistance (36, 37) and acknowledges
the need for a more long-term study on the antifungal activity
of triazole derivatives in the treatment of A. fumigatus in indi-
viduals with CF.
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